Boehringer Ingelheim Collaborates with Healx to Identify New Treatments for Rare Neurological Diseases
Shots:
- BI and Healx team up to discover new indications targeting rare neurological diseases by harnessing Healx’s AI-based drug discovery platform- Healnet to advance BI’s pipeline
- The collaboration combines BI’s expertise for drug development- especially in rare neurological conditions with Healx’s AI-powered drug discovery platform. Healx will utilize its data analysis and technological capabilities to help BI in prioritizing selected indications for further research
- Additionally- Healx has its experience in fragile X syndrome as well as Pitt-Hopkins syndrome and has identified 8 drug candidates for fragile X syndrome leveraging Healnet- out of which 1 is progressing towards P-IIa study
Click here to read full press release/ article | Ref: Healx | Image: Crunchbase
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com